No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 39 of the 40 quarters in the window, leaving 1 comparable quarter; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T19:08:26.201Z. Latest historical point 2023-01-19. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T19:08:26.201Z. Latest historical point 2023-01-19. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Tenax Therapeutics, Inc. (TENX) stock was $1.93 as of Oct 6, 2026, 3:05 PM EDT, down 1.53% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -73.8% · 3-year avg -55.8%/yr · 5-year avg -76.8%/yr
Tenax Therapeutics, Inc. is a specialized pharmaceutical enterprise dedicated to discovering, advancing, and bringing to market therapies for cardiovascular and pulmonary conditions throughout the United States and Canada.
Biotechnology · Chapel Hill, NC
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2013-04-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2013-04-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.35
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.35
vs Estimate
$-0.36
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TENX | $51.19M | $1.93 | -1.53% | -73.82% | -76.80% | -64.85% | N/A |
| 2ELOX | $50.99M | $14.84 | -3.70% | N/A | N/A | N/A | vs TENX |
| 3EXOZ | $51.51M | $5.55 | +0.54% | -58.32% | N/A | N/A | vs TENX |
| 4BTMD | $51.83M | $1.18 | +4.91% | -62.24% | -35.12% | N/A | vs TENX |
| 5COCH | $50.38M | $0.65 | +0.25% | -19.94% | -41.73% | N/A | vs TENX |
| 6CLNN | $50.28M | $3.94 | +0.64% | -62.62% | -51.16% | N/A | vs TENX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 9 analysts
Average Price Target
$12.56
+550.5% upside
Low
$4.00
Current
$1.93
High
$36.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.38 | $-0.36 | $-0.34 | 5 |
| Quarter ending Dec 2026 | $-0.42 | $-0.38 | $-0.36 | 5 |
| Quarter ending Mar 2027 | $-0.39 | $-0.39 | $-0.39 | 3 |
| Quarter ending Jun 2027 | $-0.39 | $-0.39 | $-0.39 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.60 | $-1.45 | $-1.21 | 7 |
| FY 2027 | $-1.56 | $-1.45 | $-1.32 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $4.16M | $4.16M | $4.16M | 9 |
| FY 2027 | $12.90M | $12.90M | $12.90M | 9 |
